278 related articles for article (PubMed ID: 20976952)
1. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
Kwiecińska-Piróg J; Bogiel T; Gospodarek E
Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
[TBL] [Abstract][Full Text] [Related]
2. [The susceptibility of Proteus mirabilis strains isolated from white stork (Ciconia ciconia)].
Kwiecińska-Piróg J; Bogiel T; Gospodarek E; Kasprzak M; Jerzak L; Kamiński P
Med Dosw Mikrobiol; 2011; 63(2):139-44. PubMed ID: 22184908
[TBL] [Abstract][Full Text] [Related]
3. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
[TBL] [Abstract][Full Text] [Related]
4. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
5. [Drug resistance and proticinogenic types of Proteus mirabilis isolated from urinary tract infections].
Szymaniak L; Aleksandrowicz I; Giedrys-Kalemba S
Med Dosw Mikrobiol; 1999; 51(3-4):323-30. PubMed ID: 10803261
[TBL] [Abstract][Full Text] [Related]
6. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
[TBL] [Abstract][Full Text] [Related]
7. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
8. Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croatia.
Sardelić S; Bedenić B; Sijak D; Colinon C; Kalenić S
Chemotherapy; 2010; 56(3):208-13. PubMed ID: 20551637
[TBL] [Abstract][Full Text] [Related]
9. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
[TBL] [Abstract][Full Text] [Related]
10. Identification of plasmid-encoded extended spectrum beta-lactamases produced by a clinical strain of Proteus mirabilis.
Mahrouki S; Ben-Achour N; Chouchani C; Ben-Moussa M; Belhadj O
Pathol Biol (Paris); 2009 May; 57(3):e55-9. PubMed ID: 18456422
[TBL] [Abstract][Full Text] [Related]
11. Differences in biofilm formation and aggregative adherence between beta-lactam susceptible and beta-lactamases producing P. mirabilis clinical isolates.
Nucleo E; Fugazza G; Migliavacca R; Spalla M; Comelli M; Pagani L; Debiaggi M
New Microbiol; 2010 Jan; 33(1):37-45. PubMed ID: 20402412
[TBL] [Abstract][Full Text] [Related]
12. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
[TBL] [Abstract][Full Text] [Related]
13. VEB-6 extended-spectrum beta-lactamase-producing Proteus mirabilis from Sultanate of Oman.
Potron A; Poirel L; Elhag K; Al Yaqoubi F; Nordmann P
Int J Antimicrob Agents; 2009 Nov; 34(5):493-4. PubMed ID: 19525094
[No Abstract] [Full Text] [Related]
14. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
[TBL] [Abstract][Full Text] [Related]
15. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
[No Abstract] [Full Text] [Related]
16. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
[TBL] [Abstract][Full Text] [Related]
17. [Prevalence of multidrug-resistant Proteus spp. strains in clinical specimens and their susceptibility to antibiotics].
Reśliński A; Gospodarek E; Mikucka A
Med Dosw Mikrobiol; 2005; 57(2):175-84. PubMed ID: 16134389
[TBL] [Abstract][Full Text] [Related]
18. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
[TBL] [Abstract][Full Text] [Related]
19. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum β-lactamase-producing Proteus mirabilis with multidrug resistance isolated from raw chicken in Singapore: Genotypic and phenotypic analysis.
Guo S; Aung KT; Tay MYF; Seow KLG; Ng LC; Schlundt J
J Glob Antimicrob Resist; 2019 Dec; 19():252-254. PubMed ID: 31639544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
